Compound: hydralazine
SMILES: n1ncc2ccccc2c1NN
InChIKey: RPTUSVTUFVMDQK-UHFFFAOYSA-N
Synonyms: hydralazine, 1-Hydrazinophthalazine, 1-Hydrazinylphthalazine, 86-54-4, Hypophthalin, Aprezolin, Hydralazin, phthalazin-1-ylhydrazine, Apresolin, Hidralazin, Hydrazinophthalazine, Hidralazina, Idralazina, 1(2H)-Phthalazinone, hydrazone, 6-Hydralazine, Hydrallazine, 1-Phthalazinylhydrazine, Hydralazinum, Phthalazine, 1-hydrazino-, Ciba 5968, Hydrazone 1(2H)-phthalazinone, Hidral, 1(2H)-Phthalazinone hydrazone, (2H)-Phthalazinone hydrazone, C 5968, NSC-126699, 26NAK24LS8, CHEBI:5775, DTXSID4023129, 5-25-17-00412 (Beilstein Handbook Reference), NSC126699, 1-hydrazinylidene-1,2-dihydrophthalazine, Hydrallazin, RefChem:55329, Hydralazine mono Hydrochloride, mono-Hydrochloride, Hydralazine, DTXCID703129, C02DB02, 201-680-3, Apresoline, 59275-69-3, (E)-1-Hydrazono-1,2-dihydrophthalazine, Apressin (pharmaceutical), C-5968, Praparat 5968, 1044569-46-1, Hydralazine (INN), NSC 126699, C-5068, (1Z)-1(2H)-Phthalazinone hydrazone, Apresolin; Apresoline; Apressin, Dihydralazine EP Impurity C, phthalazinylhydrazine, Idralazina [DCIT], phthalazine, 1-hydrazino-, hydrochloride, Idralazina [Italian], Hidralazina [Spanish], HYDRALAZINE [INN], (E)-1-Hydrazineylidene-1,2-dihydrophthalazine, (Z)-1-Hydrazineylidene-1,2-dihydrophthalazine, (Z)-1-Hydrazono-1,2-dihydrophthalazine hydrochloride, Hydralazine [INN:BAN], Hydralazinum [INN-Latin], Hidralazina [INN-Spanish], HLZ, Hidral (TN), CCRIS 5385, MFCD00135998, NCGC00015501-02, CAS-304-20-1, EINECS 201-680-3, BRN 0132615, UNII-26NAK24LS8, phthalazone hydrazone, Hydralazine polistirex, Ophthazin Impurity 1, 1-hydrazonophthalazine, Spectrum_000875, HYDRALAZINE [MI], Prestwick0_000169, Prestwick1_000169, Prestwick2_000169, Spectrum2_000969, Spectrum3_000455, Spectrum4_000005, Spectrum5_000822, Lopac-H-1753, HYDRALAZINE [IARC], Epitope ID:137349, HYDRALAZINE [VANDF], SCHEMBL7810, NCIOpen2_001484, Lopac0_000593, Oprea1_207681, Oprea1_416878, BSPBio_002130, HYDRALAZINE [WHO-DD], KBioGR_000349, KBioSS_001355, WLN: T66 CNNJ BMZ, DivK1c_000117, SPBio_000977, SPBio_001958, Discontinued See: H716531, CHEMBL276832, GTPL7326, orb1308014, orb1705271, SCHEMBL2609687, SCHEMBL6617758, SCHEMBL6617760, BDBM81461, HY-B0464A, KBio1_000117, KBio2_001355, KBio2_003923, KBio2_006491, KBio3_001350, RPTUSVTUFVMDQK-UHFFFAOYSA-, 1(2H)-Phthalazinone hydrazone #, NINDS_000117, ALBB-023848, NSC_3637, EBC-26110, SBB071765, STK246900, Hydralazine; phthalazin-1-ylhydrazine, AKOS000122609, AKOS016843064, AKOS028109138, CCG-204682, DB01275, SDCCGSBI-0050575.P005, CAS_86-54-4, IDI1_000117, NCGC00015501-01, NCGC00015501-03, NCGC00015501-04, NCGC00015501-05, NCGC00015501-06, NCGC00015501-07, NCGC00015501-17, NCGC00162199-01, LS-13412, SBI-0050575.P004, DB-328941, CS-0013620, NS00007527, ST45026967, EN300-34025, (1E)-1-hydrazinylidene-1,2-dihydrophthalazine, C07040, D08044, AB00053483_03, AB01274815-01, AB01274815_02, Q419987, BRD-K82103381-003-03-7, BRD-K82103381-003-06-0, BRD-K82103381-003-07-8, BRD-K82103381-003-08-6, BRD-K82103381-003-09-4, DIHYDRALAZINE SULFATE, HYDRATED IMPURITY B [EP IMPURITY], InChI=1/C8H8N4/c9-11-8-7-4-2-1-3-6(7)5-10-12-8/h1-5H,9H2,(H,11,12)
Theoretical properties:
molecular_formula: C8H8N4
molecular_weight: 160.18 g/mol
exact_mass: 160.074896272 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 2
hydrogen_bond_acceptor_count: 4
rotatable_bond_count: 1
heavy_atom_count: 12
topological_polar_surface_area: 63.8 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
melting_point: 172-173 °C
solubility: <1mg/mL
Descriptions:
pubchem: Hydralazine is the 1-hydrazino derivative of phthalazine; a direct-acting vasodilator that is used as an antihypertensive agent. It has a role as a vasodilator agent and an antihypertensive agent. It is a member of hydrazines, a member of phthalazines, an azaarene and an ortho-fused heteroarene.
chebi: The 1-hydrazino derivative of phthalazine; a direct-acting vasodilator that is used as an antihypertensive agent.
chembl: HYDRALAZINE is a small molecule listed in the ChEMBL database and has reached clinical trial phase 4.0.
wikipedia: Hydralazine, sold under the brand name Apresoline among others, is a medication used to treat high blood pressure and heart failure. This includes high blood pressure in pregnancy and very high blood pressure resulting in symptoms. It has been found to be particularly useful in heart failure, together with isosorbide dinitrate, for treatment of people of African descent. It is given by mouth or by injection into a vein. Effects usually begin around 15 minutes and last up to six hours.
Common side effects include headache and fast heart rate. It is not recommended in people with coronary artery disease or in those with rheumatic heart disease that affects the mitral valve. In those with kidney disease a low dose is recommended. Hydralazine is in the vasodilator family of medications, so it is believed to work by causing the dilation of blood vessels.
Hydralazine was discovered while scientists at Ciba were looking for a treatment for malaria. It was patented in 1949. It is on the World Health Organization's List of Essential Medicines. In 2023, it was the 109th most commonly prescribed medication in the United States, with more than 6 million prescriptions.